DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Antioxidative potential of a combined therapy of anti TNFalpha and Zn acetate in experimental colitis.

Author(s): Barollo M, Medici V, D'Inca R, Banerjee A, Ingravallo G, Scarpa M, Patak S, Ruffolo C, Cardin R, Sturniolo GC

Affiliation(s): Department of Surgical and Gastroenterological Sciences, University of Padova, Padova 35128, Italy.

Publication date & source: 2011-09-28, World J Gastroenterol., 17(36):4099-103.

Publication type: Research Support, Non-U.S. Gov't

AIM: To evaluate whether combination therapy with anti-tumour necrosis factor alpha (TNFalpha) antibody and Zn acetate is beneficial in dextran sodium sulphate (DSS) colitis. METHODS: Colitis was induced in CD1-Swiss mice with 5% DSS for 7 d. The experimental mice were then randomised into the following subgroups: standard diet + DSS treated (induced colitis group); standard diet + DSS + subcutaneous 25 mug anti-TNFalpha treated group; Zn acetate treated group + DSS + subcutaneous 25 mug anti-TNFalpha; standard diet + DSS + subcutaneous 6.25 mug anti-TNFalpha treated group and Zn acetate treated group + DSS + subcutaneous 6.25 mug anti-TNFalpha. Each group of mice was matched with a similar group of sham control animals. Macroscopic and histological features were scored blindly. Homogenates of the colonic mucosa were assessed for myeloperoxidase activity as a biochemical marker of inflammation and DNA adducts (8OH-dG) as a measure of oxidative damage. RESULTS: DSS produced submucosal erosions, ulcers, inflammatory cell infiltration and cryptic abscesses which were reduced in both groups of mice receiving either anti-TNFalpha alone or combined with zinc. The effect was more pronounced in the latter group (vs Zn diet, P < 0.02). Myeloperoxidase activity (vs controls, P < 0.02) and DNA adducts, greatly elevated in the DSS fed colitis group (vs controls, P < 0.05), were significantly reduced in the treated groups, with a more remarkable effect in the group receiving combined therapy (vs standard diet, P < 0.04). CONCLUSION: DSS induces colonic inflammation which is modulated by the administration of anti-TNFalpha. Combining anti-TNFalpha with Zn acetate offers marginal benefit in colitis severity.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017